"By harnessing the power of single-cell analysis, we can gain deeper understanding of various NCDs"

Single cell analysis is revolutionising fundamental biological research, paving the way for effective personalised treatments and precise interventions. By systematically investigating cellular heterogeneity, researchers are gaining unprecedented insights into gene mutations, cellular interactions, regulatory mechanisms, and molecular pathways that drive disease progression. BioSpectrum Asia spoke to Tony Acciarito, President, Asia-Pacific & Japan, Thermo Fisher Scientific to gain more insights into the future of this promising technology. Edited excerpts:

- Dr Manbeena Chawla

How is the single cell analysis market evolving in the Asia Pacific (APAC) region and contributing to life sciences research there? 

Within the Asia Pacific region, single-cell analysis continues to make a profound impact, particularly in oncology, immunology, and stem cell research. In fact, the region accounted for 22.6 per cent of the global single-cell analysis market in 2022 and is projected to grow at the highest CAGR of 17.5 per cent by 2028.

With one of the largest and most established pharma industries in the region, Japan presents tremendous opportunities for the adoption of single-cell analysis in the development and manufacture of drugs and vaccines.

India on the other hand, is focusing on improving healthcare outcomes. Through strategic investments in basic and translational research, academia-industry collaboration, and providing regulatory frameworks, the government is committed to strengthen the pharma and biotech sectors, ushering avenues for adoption of single-cell analysis.

Singapore, known as a prominent biotech R&D hub, is establishing itself as a leading centre for clinical research in cancer, neurological diseases, and infectious diseases. This ambitious goal will undoubtedly fuel the demand for single-cell analysis products in the market.

South Korea’s ambitious target to triple exports and global market share of pharmaceuticals and medical instruments by 2030, is driving increased R&D investments, fostering innovation in therapeutics, and amplifying the adoption of single-cell analysis technologies.